Evidence map›Paper›PMID 42749879›Full record

ArticleExperimental & molecular medicine2026

Author Correction: SET/PP2A signaling regulates macrophage positioning in hypoxic tumor regions by amplifying chemotactic responses.

Shaolong Zhang, Jingping Zhou, Pengzhao Shang, Guomeng Zhao, Anlei Wang, Jinlei Mao, Yuhang Tao, Ziyi Chen, Xuehao Wang, Changying Guo

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Shaolong Zhang *School of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China.
Jingping Zhou *School of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China.
Pengzhao ShangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China.
Guomeng ZhaoSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China.
Anlei WangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China.
Jinlei MaoSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China.
Yuhang TaoSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China.
Ziyi ChenHepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China. dr_czy@126.com.
Xuehao WangHepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China. wangxh@njmu.edu.cn.
Changying GuoSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, PR China. guocha@cpu.edu.cn.ORCID http://orcid.org/0000-0002-7992-565X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42749879
PMCPMC13633285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.